Telios Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Plans to use part of an anticipated $6.7 mil. in net proceeds from offering of 3 mil. units to support "ongoing and planned clinical trials" of Argidene Gel, a treatment for diabetic foot ulcers (previously called Telio-Derm), and TP-9201, which is being developed to treat conditions associated with platelet aggregation, the San Diego-based company says in a prospectus for the offering. Telios submitted a premarket approval application for Argidene Gel in March 1993 ("The Gray Sheet" April 5, 1993, In Brief) and has filed an investigational new drug application for TP-9201. The proceeds also will be used for scheduled repayments of obligations under equipment leases and notes payable. Each unit in the offering consists of one share of convertible preferred stock and one warrant to purchase a share of common stock. The placement agent for the offering is Hambrecht & Quist
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.